A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1525-1532

  Sandstrom K ^a   Haylock, A K ^a   Spiegelberg, D ^a   Qvarnstrom F ^a   Wester, K ^a   Nestor, M ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antibody fragment; CD44v6; F(ab') 2; Fab'; Head and neck squamous cell carcinoma; Radioimmunodiagnosis; Radioimmunotargeting

Indexed keywords

ANTIBODY; CD44V6 ANTIGEN; IODINE 125;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; HEAD AND NECK CANCER; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; AUTORADIOGRAPHY; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HALF-LIFE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84860299128     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1352     Document Type: Article

References (39)

1. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955, 2000.
2. Whitehurst JO and Droulias CA: Surgical treatment of squamous cell carcinoma of the oral tongue: factors influencing survival. Arch Otolaryngol 103: 212-215, 1977. (Pubitemid 8086413)
3. Connell CA, Corry J, Milner AD, et al: Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 29: 986-995, 2007.
4. 18F-FDG PET in oncology. J Nucl Med 49: 480-508, 2008.
5. Brouwer J, Hooft L, Hoekstra OS, et al: Systematic review: accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. Head Neck 30: 889-897, 2008. (Pubitemid 352008949)
6. Shreve PD, Anzai Y and Wahl RL: Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19: 61-77, 1999.
7. Terpe HJ, Storkel S, Zimmer U, et al: Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol 148: 453-463, 1996. (Pubitemid 26056730)
8. Gunthert U, Hofmann M, Rudy W, et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991. (Pubitemid 121001209)
9. Kainz C, Kohlberger P, Tempfer C, et al: Prognostic value of CD44 splice variants in human stage III cervical cancer. Eur J Cancer 31A: 1706-1709, 1995.
10. Heider KH, Mulder JW, Ostermann E, et al: Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur J Cancer 31A: 2385-2391, 1995. (Pubitemid 26050584)
11. Fox SB, Fawcett J, Jackson DG, et al: Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 54: 4539-4546, 1994. (Pubitemid 24273174)
12. Schrijvers AH, Quak JJ, Uyterlinde AM, et al: MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 53: 4383-4390, 1993.
13. Borjesson PK, Jauw YW, Boellaard R, et al: Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 12: 2133-2140, 2006.
14. De Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB and van Dongen GA: Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1: 591-598, 1995.
15. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 41: 1999-2010, 2000.
16. Borjesson PK, Postema EJ, Roos JC, et al: Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9: S3961-S3972, 2003.
17. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50: S814-S819, 1990.
18. Thurber GM, Zajic SC and Wittrup KD: Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48: 995-999, 2007. (Pubitemid 46909929)
19. Schmidt MM and Wittrup KD: A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8: 2861-2871, 2009.
20. 2, and Fab' in mice. Cancer Res 46: 3969-3978, 1986.
21. Brakenhoff RH, van Gog FB, Looney JE, van Walsum M, Snow GB and van Dongen GA: Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol Immunother 40: 191-200, 1995.
22. Nestor M, Persson M, Cheng J, et al: Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods. Bioconjug Chem 14: 805-810, 2003. (Pubitemid 36875441)
23. Paavilainen L, Wernerus H, Nilsson P, et al: Evaluation of monospecific antibodies: a comparison study with commercial analogs using immunohistochemistry on tissue microarrays. Appl Immunohistochem Mol Morphol 16: 493-502, 2008.
24. Behr TM, Blumenthal RD, Memtsoudis S, et al: Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res 6: 4900-4907, 2000.
25. 2 and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. Nucl Med Biol 34: 257-265, 2007.
26. 2 fragments in tumor-bearing athymic mice. Anticancer Res 11: 2051-2057, 1991.
27. 2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm 18: 931-940, 2003.
28. 2 in head and neck tumors. J Nucl Med 51: 1076-1083, 2010.
29. Murray JL, Rosenblum MG, Zhang HZ, et al: Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. Cancer 73: 850-857, 1994. (Pubitemid 24046641)
30. 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med 41: 1657-1663, 2000.
31. De Bree R, Roos JC, Quak JJ, et al: Clinical imaging of head and neck cancer with technetium-99m-labeled monoclonal antibody E48 IgG or F(ab')2. J Nucl Med 35: 775-783, 1994. (Pubitemid 24151211)
32. 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 50: 1828-1836, 2009.
33. Wang SJ, Wong G, de Heer AM, Xia W and Bourguignon LY: CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 119: 1518-1530, 2009.
34. Fortin MA, Salnikov AV, Nestor M, Heldin NE, Rubin K and Lundqvist H: Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging 34: 1376-1387, 2007. (Pubitemid 47312573)
35. Burvenich IJ, Schoonooghe S, Blanckaert P, et al: Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. Nucl Med Biol 34: 257-265, 2007. (Pubitemid 46441854)
36. Nestor M, Sundstrom M, Anniko M and Tolmachev V: Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas. Nucl Med Biol 38: 103-112, 2011.
37. Fortin MA, Salnikov AV, Nestor M, Heldin NE, Rubin K and Lundqvist H: Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging 34: 1376-1387, 2007. (Pubitemid 47312573)
38. Wochner RD, Strober W and Waldmann TA: The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 126: 207-221, 1967.
39. Holechek MJ: Glomerular filtration: an overview. Nephrol Nurs J 30: 285-291, 2003.